Imiquimod is a medication successfully used in the treatment of skin diseases. In addition to its known mechanism of action, it also triggers other processes in the body. Scientists at the Technical University of Munich (TUM) have succeeded in explaining the molecular fundamentals of these additional effects. The results also shine a new light on other known molecular processes which could indicate an approach to the treatment of inflammatory illnesses.
The fact that a given medication has been approved for use doesn't automatically mean that all of its mechanisms of action have been completely investigated and understood. New findings and technical possibilities continuously enable more precise insights into the processes that take place within the human body. As a result, we constantly gain a better understanding of how known medicines work and what approaches could be practical for new medications.
PD Dr. Olaf Groß, group leader at the TUM Institute for Clinical Chemistry and Pathobiochemistry , has been working together with his team to investigate Imiquimod. This medication has been successfully used to treat viral skin infections and certain types of skin cancer since 1997. The scientists have now published their results in the journal "Immunity".
Imiquimod is an immunomodulatory agent, which means it triggers an immune reaction which causes the body's immune system to attack modified cells. For several years, this process was the medication's only known mechanism of action. However, in the meantime it has been shown that imiquimod also triggers other processes in the body. On one hand, imiquimod directly impairs the growth of cancer cells.
On the other hand, Imiquimod activates a complex within cells of the immune system termed the inflammasome. While the inflammasome is very important for our body’s ability to defend against infection, uncontrolled activation of the inflammasome can lead to inflammatory diseases. "We think that these other mechanisms of action of Imiquimod might contribute to the efficacy or adverse side effects of the medication," says Olaf Groß.
Intervention in the mitochondria
Imiquimod specifically activates the NLRP3 inflammasome, which is a special type of inflammasome that responds to tissue stress and cellular damage. Olaf Groß and his team were able to show that NLRP3 is activated because Imiquimod impairs the respiratory chain in mitochondria. The respiratory chain is a series of mitochondrial protein complexes that generates the energy, in the form of a molecule called adenosine triphosphate, or ATP for short, that cells need to survive.
"Inhibition of the respiratory chain by imiquimod not only impairs ATP production, but also results in the production of toxic oxygen radicals," explains Dr. Ritu Mishra, one of the two primary authors of the study. "Imiquimod causes an especially large amount of radicals to be released. In contrast to other substances that intervene in the respiratory chain but generate a lower amount of radicals, here a threshold value is exceeded that results in the activation of NLRP3."
Implications for anti-inflammatory medications
"There is a lot of excitement about generating new anti-inflammatory medications by targeting the NLRP3 inflammasome," says Dr. Christina J. Groß, also one of the study's primary authors. "We hope that our research will lead to the design of medications that can prevent dangerous hyperactivation of the NLRP3 inflammasome that may occur in diseases like gout and multiple sclerosis." Olaf Groß and his team are following-up on this study by investigating whether the effect of imiquimod on the mitochondria is the mechanism behind the unexplained finding that imiquimod directly inhibits growth of cancer cells. After that, they plan to investigate new chemical substances related to Imiquimod in order to find out how the various effects of the medication can be uncoupled.
C.J. Groß, R. Mishra, K.S. Schneider, G. Médard, J. Wettmarshausen, D.C. Dittlein, H. Shi, O. Gorka, P.-A. Koenig, S. Fromm, G. Magnani, T. Ćiković, L. Hartjes, J. Smollich, A.A.B. Robertson, M.A. Cooper, M. Schmidt-Supprian, M. Schuster, K. Schroder, P. Broz, C. Traidl-Hoffmann, B. Beutler, B. Kuster, J. Ruland, S. Schneider, F. Perocchi, O. Groß. "K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria". Immunity (2016). DOI: http://dx.doi.org/10.1016/j.immuni.2016.08.010
PD Dr. rer. nat. Olaf Groß
Institute for Clinical Chemistry and Pathobiochemistry
Klinikum rechts der Isar
Technical University of Munich
+49 89 4140-4874
Dr. Ulrich Marsch | Technische Universität München
Don't Give the Slightest Chance to Toxic Elements in Medicinal Products
23.03.2018 | Physikalisch-Technische Bundesanstalt (PTB)
North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Life Sciences
23.03.2018 | Materials Sciences
23.03.2018 | Process Engineering